SAHPRA Approves Pfizer’s Paxlovid COVID-19 Treatment
SAHPRA announced the registration of Paxlovid COVID-19 treatment, an anti-viral medicine manufactured by Pfizer, to treat COVID-19. This is a 5-day oral treatment for mild to moderate COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progression to severe COVID-19.
International sources provide guidelines regarding prescribing in liver and kidney disease as well as possible drug interactions including statin therapy, anticoagulation and some hormonal birth control treatments.
Recent Posts
Advancing Kidney Transplant Transparency Through Patient Involvement
Enhancing Kidney Transplant Transparency
In a
Accelerated UK Clinical Trial Reforms: Enhancing Approvals with AI and Efficiency
UK Clinical Trial Reforms Slash Approval Times
UK Clinical Trial Reforms have accelerated clinical trial approvals, reducing average times from 91 days to 41 days through risk-proportionate changes at the Medicines and Healthcare produ...
AI in South African Healthcare: Professionals’ Confidence in Reducing Admissions and Enhanc...
AI Optimism in South Africa's Healthcare Landscape
AI in South African Healthcare is gaining momentum, as evidenced by the Philips Future Health Index (FHI...